More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

Janet Woodcock, Acting Commissioner of the FDA, provides an update on the FDA’s inspection activity during the COVID-19 pandemic, including what new tools the agency has used for inspections, which has included a mix of mission-critical, on-site...

Congress introduced legislation last week (March 23, 2021) to lower prescription drug pricing in the US. The measures include tying US drug pricing to other industrialized countries, allowing the US government to negotiate drug pricing under...

The need to improve supply-chain resilience in wake of disruptions caused by COVID-19 has caused a re-assessment of supply chains and manufacturing networks. What role will digital tools, such as artificial intelligence, advanced analytics, and...

The European Commission held a kick-off meeting of the structured dialogue process of the EU’s Pharmaceutical Strategy to address ways to improve the resilience of the EU's pharmaceutical manufacturing value chain. High-level representatives from...

What were some of the key capital investments in manufacturing by the pharmaceutical majors globally in 2020 and 2021 to date? Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an...

This week (March 15, 2021), the European Council endorsed a new chemicals strategy to set a long-term vision for the European Union’s (EU) chemicals policy. It is asking the European Commission to implement several actions, including streamlining...

Three COVID-19 vaccines by Pfizer/BioNTech, Moderna, and J&J have been authorized for emergency use in the US. What are the supply targets for 2021 and beyond, and what manufacturing networks (internal and external) are being used? DCAT Value...